Isu Abxis Obtains Patent in China for 'ISU104', an ErbB3-Targeting Anticancer Drug
[Asia Economy Reporter Lee Seon-ae]ISU Abxis announced on the 25th that it has received a patent decision from the China National Intellectual Property Administration (CNIPA) for 'ISU104,' which is being developed to target 'ErbB3' positive cancer.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
The patent pertains to 'an antibody that specifically binds to ErbB3 for the treatment of cancers with activated or overexpressed ErbB3 and resistant to anticancer drugs inhibiting ErbB1 or ErbB2.'
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
